Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 12:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 136 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Namenda/Memantine Clear all
Completed Phase 2 Interventional

A Placebo-Controlled Trial of Memantine for Alcohol Dependence

NCT00246415
View directory record Official record
Conditions
Alcohol Dependence (Primary Condition), Alcohol Abuse
Interventions
Memantine
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2008 · Synced Oct 6, 2026, 12:59 PM EDT
Completed Phase 2 Interventional

An Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder

NCT00106405
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Memantine HCl
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
6
States / cities
National City, California • Baltimore, Maryland • Saint Charles, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 6, 2026, 12:59 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

NCT01592786
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
72
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Oct 6, 2026, 12:59 PM EDT
Terminated Phase 3 Interventional Results available

Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

NCT04588246
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Breast Neoplasm, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Memantine, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
79
States / cities
Tucson, Arizona • Corona, California • Duarte, California + 63 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 6, 2026, 12:59 PM EDT
Completed Phase 2 Interventional Results available

Memantine Treatment Study of Pathological Gambling

NCT00585169
View directory record Official record
Conditions
Pathological Gambling
Interventions
Memantine Hydrochloride
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Oct 6, 2026, 12:59 PM EDT
Terminated Phase 2 Interventional Results available

Memantine for Recurrent Glioblastoma

NCT01260467
View directory record Official record
Conditions
Glioblastoma
Interventions
memantine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 6, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Results available

Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases

NCT02360215
View directory record Official record
Conditions
Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain, Solid Neoplasm
Interventions
Whole brain radiation therapy with hippocampal avoidance, Memantine, Whole brain radiation therapy
Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
212
States / cities
Tuscaloosa, Alabama • Gilbert, Arizona • Tucson, Arizona + 172 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 6, 2026, 12:59 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Memantine Augmentation of Targeted Cognitive Training in Schizophrenia

NCT04857983
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 6, 2026, 12:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Treatment Resistant Geriatric Depression in Primary Care

NCT01392287
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Memantine
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
55 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 6, 2026, 12:59 PM EDT
Completed Phase 4 Interventional Results available

Memantine Augmentation of Antidepressants

NCT00344682
View directory record Official record
Conditions
Depressive Disorder
Interventions
memantine, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 85 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 6, 2026, 12:59 PM EDT
Completed Phase 2 Interventional Results available

Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism

NCT00872898
View directory record Official record
Conditions
Autism
Interventions
Memantine - Extended Release (ER), Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 18 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
17
States / cities
Phoenix, Arizona • Sacramento, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Oct 6, 2026, 12:59 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?

NCT00988663
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
memantine, Placebo
Drug
Lead sponsor
Jerrry L Lewis
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 6, 2026, 12:59 PM EDT
Recruiting Phase 2 Interventional

NTS-WBRT in Brain Metastases

NCT05013892
View directory record Official record
Conditions
Brain Metastases
Interventions
NTS-WBRT (normal tissue sparing whole brain radiation therapy), Memantine
Radiation · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 6, 2026, 12:59 PM EDT
Completed No phase listed Observational

Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment

NCT01364818
View directory record Official record
Conditions
Autism Spectrum Disorders, Psychosis, Fragile X Syndrome
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 6, 2026, 12:59 PM EDT
Completed Phase 4 Interventional

An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder

NCT02258828
View directory record Official record
Conditions
PTSD
Interventions
Memantine, Placebo
Drug
Lead sponsor
Sriram Ramaswamy
Federal
Eligibility
19 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 22, 2020 · Synced Oct 6, 2026, 12:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Functional Neuroimaging of Alcoholism Vulnerability (PIT)

NCT01585168
View directory record Official record
Conditions
Healthy
Interventions
Memantine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 35 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 6, 2026, 12:59 PM EDT
Completed Not applicable Interventional Results available

Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study

NCT01533493
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Executive Function Deficits (EFD)
Interventions
Placebo, Memantine Hydrochloride, OROS-Methylphenidate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 6, 2026, 12:59 PM EDT
Withdrawn Not applicable Interventional

Efficacy and Safety of the Use of Memantine for Preserving Cognition in Adult Patients With Epilepsy

NCT00986115
View directory record Official record
Conditions
Epilepsy
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 6, 2026, 12:59 PM EDT
Completed Phase 2 Interventional Results available

Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine

NCT01592747
View directory record Official record
Conditions
Autistic Disorder, Autism, Asperger's Disorder, Asperger Syndrome, Autism Spectrum Disorders, Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl), Placebo capsules
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
64
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 6, 2026, 12:59 PM EDT
Active, not recruiting Phase 3 Interventional

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

NCT04804644
View directory record Official record
Conditions
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Memantine Hydrochloride, Neurocognitive Assessment, Stereotactic Radiosurgery, Survey Administration, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
227
States / cities
Phoenix, Arizona • Anaheim, California • Bellflower, California + 172 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 6, 2026, 12:59 PM EDT
Completed Phase 2 Interventional Results available

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

NCT02580305
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
SUVN-502, Placebo, Donepezil, Memantine
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
71
States / cities
Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 6, 2026, 12:59 PM EDT
Enrolling by invitation Phase 4 Interventional

Quality Improvement and Practice Based Research in Neurology Using the EMR

NCT02670161
View directory record Official record
Conditions
Brain Tumors, Epilepsy, Migraine, Mild Cognitive Impairment, Concussion, Multiple Sclerosis, Neuropathy, Parkinson's, Restless Legs Syndrome, Stroke
Interventions
Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 100 Years
Enrollment
3,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 6, 2026, 12:59 PM EDT
Withdrawn Early Phase 1 Interventional

Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD)

NCT04966546
View directory record Official record
Conditions
Chronic Subdural Hematoma
Interventions
Memantine Hydrochloride, Placebo
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 6, 2026, 12:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia

NCT01555697
View directory record Official record
Conditions
Schizophrenia
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 6, 2026, 12:59 PM EDT